- Vaxcyte (PCVX) on Thursday said that it has commenced an underwritten public offering of $500 million of common stock and pre-funded warrants.
- The clinical-stage vaccine developer said all securities in the offering will be sold by the company and that
Vaxcyte launches proposed $500M public offering of stock, warrants
